BrightKaire Featured in Calcalist Tech: Israeli Startup NeuroKaire Launches World’s First Blood Test to Personalize Depression Treatment

For patients with depression, finding the right antidepressant often involves months of uncertainty and repeated medication changes. In this feature, Calcalist Tech examines how NeuroKaire is working to eliminate that guesswork with BrightKaire™, a first-of-its-kind blood test designed to personalize antidepressant treatment.

The article highlights NeuroKaire’s innovative approach, which transforms a patient’s blood cells into neurons and uses artificial intelligence to analyze how those cells respond to different antidepressants. By providing clinicians with individualized treatment insights before medication is prescribed, BrightKaire aims to shorten the path to effective care and improve outcomes for patients living with depression.

Calcalist Tech’s coverage underscores the growing convergence of biotechnology, AI, and neuroscience, while showcasing NeuroKaire’s mission to make precision psychiatry a reality for patients and providers worldwide.

👉 Read the full article

‍